about
A locked nucleic acid antisense oligonucleotide (LNA) silences PCSK9 and enhances LDLR expression in vitro and in vivoAnnexin A2 is a natural extrahepatic inhibitor of the PCSK9-induced LDL receptor degradationIdentification of heterogeneous nuclear ribonucleoprotein K as a transactivator for human low density lipoprotein receptor gene transcriptionHepatocyte nuclear factor 1alpha plays a critical role in PCSK9 gene transcription and regulation by the natural hypocholesterolemic compound berberineCholesterol: the good, the bad, and the ugly - therapeutic targets for the treatment of dyslipidemiaIdentification of a Small Peptide That Inhibits PCSK9 Protein Binding to the Low Density Lipoprotein ReceptorPCSK9 Promotes oxLDL-Induced PC12 Cell Apoptosis Through the Bcl-2/Bax-Caspase 9/3 Signaling Pathway.High-dose atorvastatin causes a rapid sustained increase in human serum PCSK9 and disrupts its correlation with LDL cholesterolWhat lies ahead for the proprotein convertases?Novel domain interaction regulates secretion of proprotein convertase subtilisin/kexin type 9 (PCSK9) protein.Inhibition of PCSK9 transcription by berberine involves down-regulation of hepatic HNF1α protein expression through the ubiquitin-proteasome degradation pathwayProprotein convertase subtilisin/kexin type 9 (PCSK9) in lipid metabolism, atherosclerosis and ischemic stroke.Strong induction of PCSK9 gene expression through HNF1alpha and SREBP2: mechanism for the resistance to LDL-cholesterol lowering effect of statins in dyslipidemic hamstersJanus kinase activation by cytokine oncostatin M decreases PCSK9 expression in liver cellsAtorvastatin increases intestinal expression of NPC1L1 in hyperlipidemic menEffects of currently prescribed LDL-C-lowering drugs on PCSK9 and implications for the next generation of LDL-C-lowering agents.Proprotein convertase subtilisin/kexin type 9 (PCSK9) can mediate degradation of the low density lipoprotein receptor-related protein 1 (LRP-1)Relation of plasma PCSK9 levels to lipoprotein subfractions in patients with stable coronary artery disease.Familial hypercholesterolemia: the lipids or the genes?PCSK9 reduces the protein levels of the LDL receptor in mouse brain during development and after ischemic stroke.Impacts of ezetimibe on PCSK9 in rats: study on the expression in different organs and the potential mechanisms.Chronic alcohol consumption disrupted cholesterol homeostasis in rats: down-regulation of low-density lipoprotein receptor and enhancement of cholesterol biosynthesis pathway in the liverAn anti-PCSK9 antibody reduces LDL-cholesterol on top of a statin and suppresses hepatocyte SREBP-regulated genesDecreased PCSK9 expression in human hepatocellular carcinoma.High-fructose feeding promotes accelerated degradation of hepatic LDL receptor and hypercholesterolemia in hamsters via elevated circulating PCSK9 levelsCETP inhibitors downregulate hepatic LDL receptor and PCSK9 expression in vitro and in vivo through a SREBP2 dependent mechanism.Identification of PCSK9 as a novel serum biomarker for the prenatal diagnosis of neural tube defects using iTRAQ quantitative proteomics.A MARCH6 and IDOL E3 Ubiquitin Ligase Circuit Uncouples Cholesterol Synthesis from Lipoprotein Uptake in Hepatocytes.Furin-cleaved proprotein convertase subtilisin/kexin type 9 (PCSK9) is active and modulates low density lipoprotein receptor and serum cholesterol levels.Immunization against proprotein convertase subtilisin-like/kexin type 9 lowers plasma LDL-cholesterol levels in mice.Low density lipoprotein binds to proprotein convertase subtilisin/kexin type-9 (PCSK9) in human plasma and inhibits PCSK9-mediated low density lipoprotein receptor degradation.Statins and ezetimibe modulate plasma proprotein convertase subtilisin kexin-9 (PCSK9) levels.The dual behavior of PCSK9 in the regulation of apoptosis is crucial in Alzheimer's disease progression (Review).Strategies for proprotein convertase subtilisin kexin 9 modulation: a perspective on recent patents.PCSK9: an emerging target for treatment of hypercholesterolemia.The role of proprotein convertase subtilisin/kexin type 9 in hyperlipidemia: focus on therapeutic implications.Proprotein convertases subtilisin/kexin type 9, an enzyme turned escort protein: hepatic and extra hepatic functions.The novel function of HINFP as a co-activator in sterol-regulated transcription of PCSK9 in HepG2 cells.Update of Clinical Trials of Anti-PCSK9 Antibodies.Effect of statin therapy on plasma proprotein convertase subtilisin kexin 9 (PCSK9) concentrations: a systematic review and meta-analysis of clinical trials.
P2860
Q21136366-98480E8E-E0E3-40C5-8F37-8AF5955549B6Q24294486-C639EE79-42F1-4156-8D70-480046A0568FQ24305958-3532A24D-44B7-4A88-AF5C-05303EE031CEQ24652495-7A199F55-3B66-46E5-8697-E1A721503852Q27013494-B1376CEA-6B17-4028-87E9-930C4FDD8299Q27680601-C424A8D8-9614-48B0-91FB-B7488A183B5FQ32179917-7EE21955-CBBE-4D25-9577-5CB79D2F35CFQ34053143-3FAACF75-D601-43CB-9B71-7F57FD6B8236Q34169463-8341F7A0-732A-4376-AE33-FA5EEB953848Q34227474-463CE662-092F-452E-A862-86A37033E50BQ34455663-DCAF37F4-122E-4DCA-B799-BE990A870ED6Q34479132-82E8A36F-099E-4144-91EC-08AE1EC76C08Q34559944-64687096-9F41-4FE0-BE64-62D7FD659E85Q34560763-79B134A0-7C76-486B-8206-B5A4C34C4158Q34560789-E945D2FD-4E64-4703-934F-256720AE9C6CQ34662589-F87E3732-23E0-4AFC-85EE-51875783A7B4Q34723257-453D7472-0074-46A5-8A1D-BCCACFF6CDC8Q34937512-587C55E0-AE6F-4047-B72C-B63EBEA76650Q35014525-984E8386-ED3C-4D18-B8C0-A66E8F4C7794Q35036348-94739D0E-B317-42C2-ABEF-A0CE74956554Q35194029-054BBB6E-3FC0-4354-A70F-F149C791015FQ35677146-5FB1085A-DF0D-48C4-9025-810352C77560Q35767551-0A084B01-6DD0-4C46-B86A-C610CCB9C289Q35870767-17C963C2-7287-4010-9773-CF2E7F84C7A3Q35911079-0447DB8E-28DC-4DD5-81BA-00AB168C7FFFQ35963040-BC284B43-BF97-41A7-B4C2-FAEB3F4A856CQ36392759-9B8538CF-208C-44A7-9095-18A192E3ABC2Q36480874-35908855-EC3C-465E-816F-02E63C4A96A7Q36481769-29AD184F-B97F-444C-B5EF-7A83E14D1CAFQ36520347-CB08CE67-D319-4BEC-9841-42A44679A140Q36708550-8865E9F5-36A1-40FC-922A-CF157BE923F5Q37348178-647E35AC-2D9F-410D-83FE-63882083FD4CQ37567746-22BD26AF-8EAD-455B-BFD9-75B003EA4BDCQ37789741-5F73EC8F-F053-4A17-B5A3-BF31B018A201Q37825903-09C9F90D-7D37-41B3-BDF1-ECC73E380E39Q37880856-B373DB6C-DB23-42A4-A594-381719DD8FC0Q38109960-45D04855-0ECE-40AD-9933-C7CA5932DF75Q38328173-C81CC9EE-723C-470C-92FA-2E0F99EBAF21Q38444379-E61B11E3-FD32-4842-A81D-8F2987AE0BC2Q38548750-66E72F93-7A6D-4333-8C6B-DD3B33F3F131
P2860
description
im November 2008 veröffentlichter wissenschaftlicher Artikel
@de
wetenschappelijk artikel
@nl
наукова стаття, опублікована в листопаді 2008
@uk
name
PCSK9 as a therapeutic target of dyslipidemia
@en
PCSK9 as a therapeutic target of dyslipidemia
@nl
type
label
PCSK9 as a therapeutic target of dyslipidemia
@en
PCSK9 as a therapeutic target of dyslipidemia
@nl
prefLabel
PCSK9 as a therapeutic target of dyslipidemia
@en
PCSK9 as a therapeutic target of dyslipidemia
@nl
P2860
P1476
PCSK9 as a therapeutic target of dyslipidemia
@en
P2860
P356
10.1517/14728220802600715
P407
P577
2008-11-21T00:00:00Z